AI Article Synopsis
Article Abstract
Purpose: Controversy exists as to if, and when, gender affirmative (GA) treatment should be offered to individuals with gender dysphoria (GD) and co-existing psychosis. Concerns exist regarding a high risk of misdiagnosis, regret afterward due to impulsive decision making, and deterioration of psychotic symptoms. This case series aims at extending the sparse literature on GA treatment in this population by identifying challenges in diagnosis and treatment and offering recommendations to overcome them.
Case Series: The authors present case descriptions of two transgender men and two transgender women in the age range of 29-57 years with a diagnosis of GD and a schizophrenia-related diagnosis. All had undergone GA treatment with a minimum follow-up of 3 years. The gender diagnosis was complicated by the fact that feelings of GD were only shared after the onset of psychosis, and GA treatment was hampered by the persistence of mild psychotic symptoms despite antipsychotic treatment. Close communication with the psychosis treating clinicians proved useful to address these problems. GA treatment was paralleled by a stabilization of psychotic symptoms, and adherence to and satisfaction with the therapy was high.
Conclusion: These case examples show that GA treatment is possible and safe in this vulnerable population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/lgbt.2016.0133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
Mol Psychiatry
January 2025
Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects.
View Article and Find Full Text PDFHospitalizations for depressive disorders in Ecuador: An eight-year nationwide analysis of trends and demographic insights.
J Affect Disord
January 2025
School of Medicine, Faculty of Health Sciences, Universidad Técnica de Manabí, Portoviejo, Manabí, Ecuador; Research Institute, Universidad Técnica de Manabí, Portoviejo, Manabí, Ecuador. Electronic address:
Background: Sociodemographic characteristics and limited mental health care access may contribute to higher depression rates in low- and middle-income countries. Aim This study aimed to analyze nationwide depressive disorder hospitalizations in Ecuador.
Methods: We assessed the sociodemographic characteristics, severity, recurrence, and duration of hospitalizations for depressive disorders.
Prevalence and patient characteristics associated with cardiovascular disease risk factor screening in UK primary care for people with severe mental illness: an electronic healthcare record study.
BMJ Ment Health
January 2025
Division of Psychiatry, University College London, London, UK.
Background: People with severe mental illness (SMI) are at increased risk of cardiovascular disease (CVD), and initiatives for CVD risk factor screening in the UK have not reduced disparities.
Objectives: To describe the annual screening prevalence for CVD risk factors in people with SMI from April 2000 to March 2018, and to identify factors associated with receiving no screening and regular screening.
Methods: We identified adults with a diagnosis of SMI (schizophrenia, bipolar disorder or 'other psychosis') from UK primary care records in Clinical Practice Research Datalink.
Paranoia and unusual sensory experiences in Parkinson's disease.
Aging Ment Health
January 2025
Department of Experimental Psychology, University of Oxford, Oxford, UK.
Objectives: There has been limited exploration into the nature and development of psychotic experiences (PEs) in Parkinson's disease (PD). We aimed to comprehensively assess the frequency, severity, and associated distress of paranoia and unusual sensory experiences (USEs) in PD, and to assess what variables are significantly associated with these experiences, focussing on psychological processes central to understanding PEs in non-PD groups.
Method: A questionnaire battery was completed by 369 individuals with PD with a mean age of 66 years and mean time since diagnosis of 5 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!